[Form 4] Evoke Pharma Inc Insider Trading Activity
Rhea-AI Filing Summary
Evoke Pharma Inc. executive Marilyn R. Carlson reported equity transactions tied to the company’s sale to QOL Medical, LLC. On December 16, 2025, purchasers completed a tender offer to acquire all outstanding Evoke Pharma common shares for $11.00 in cash per share, followed by a merger on December 17, 2025 that made Evoke a wholly owned subsidiary of QOL Medical.
Carlson, the company’s Chief Medical Officer, reported the disposition of 360 shares of common stock and the cancellation of stock options covering 17,291 and 11,000 shares. Under the merger agreement, each outstanding stock option became fully vested and was converted into the right to receive a cash payment equal to the number of underlying shares multiplied by the difference between the $11.00 offer price and the option’s exercise price.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 17,291 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 11,000 | $0.00 | -- |
| U | Common Stock | 360 | $0.00 | -- |
Footnotes (1)
- On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price"). After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
